In this month's issue... our share tips for June 2025, the latest on our Aggressive Portfolio IX, plus company features and market insight.
There must be some sort of ANGLE!
Shares in the AIM-quoted liquid biopsy company ANGLE (7.25p) stand at very close to the all-time low and for those investors who like to take a high-degree of risk we believe that they are worth a look. Like many companies developing new medical technologies, the company has spent years in research and development, but it does seem that it is now getting closer to some sort of success, and it is odd the shares do not
reflect this.
ANGLE is a world-leading liquid biopsy company which has developed its own proprietary platform, Parsortix®, which can capture and…
CONTINUED IN THE FULL NEWSLETTER CLICK TO READ
